
Biogen Inc. (BIIB)
132.75 USD +5.22 (+4.09%) Volume: 1.91M
Biogen Inc.’s stock price sees a promising surge of +4.09% this trading session, bringing the price to 132.75 USD with a trading volume of 1.91M, despite a year-to-date decrease of -13.19%, highlighting the stock’s potential for recovery and growth.
Latest developments on Biogen Inc.
Biogen Inc. stock experienced a strong trading day, outperforming its competitors, following the announcement of a significant partnership with City Therapeutics in a deal worth over $1 billion. The strategic research collaboration aims to develop novel RNAi-based therapies, marking a shift in Biogen’s Zurzuvae strategy as OB/GYNs take on a more prominent role. This partnership comes as Biogen taps into City Therapeutics’ technology for RNAi therapies, expanding its presence in the field of CNS disease treatments. With this new venture, Biogen continues to make strides in the development of innovative treatments, attracting the attention of investors like Siemens Fonds Invest GmbH and PKO Investment Management Joint Stock Co.
A look at Biogen Inc. Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Biogen Inc. has been given a high score for its value, indicating a positive long-term outlook for the company in terms of its financial health and stability. This suggests that Biogen is a strong investment option for those looking for a company with good value potential. However, the company’s low dividend score may not be as attractive to investors seeking regular income from their investments. Despite this, Biogen has scored moderately well in growth, resilience, and momentum, indicating a promising future for the company in terms of its ability to grow, withstand challenges, and maintain positive market momentum.
Biogen Inc. is a pharmaceutical company that focuses on developing therapies for neurology, oncology, and immunology. Their products target a range of diseases including multiple sclerosis, non-hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis. With a strong emphasis on research and development, Biogen continues to innovate and bring new treatments to market. The company’s Smart Scores reflect a solid overall outlook, with particular strengths in value and resilience. Investors may see Biogen as a promising opportunity for long-term growth and potential returns.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars